Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE004 (DEU) (Dr. Tanaka)
· consented 2022-03-03
Adverse events
4
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-04-23 (study day 32); relationship: N
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-04-30 (study day 39); relationship: N
severe
serious
assessed
2026-08-18
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-28 (study day 128); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 162); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.